BEDFORD, Mass.--(BUSINESS WIRE)--Oct. 17,
2006--Cambridge Heart, Inc. (OTCBB-CAMH) announced today that a conference call has been
scheduled for November 2, 2006 at 4:30 p.m. eastern to discuss the Company's third quarter
financial results, as well as recent Company developments. The call will be hosted by Mr.
Jeffery Langan, the Company's President and CEO, and Mr. Roderick de Greef, its Chief
Financial Officer. Interested parties may participate by dialing (866) 356-4279 or (617)
597-5394 from outside the U.S. utilizing Passcode 82383362.Persons unable to
participate may listen to a recorded replay at any time during the 48 hours immediately
following the conference call by dialing (888) 286-8010 or (617) 801-6888 from outside the
U.S. The code for the replay is 44763245. The replay will be available beginning
approximately two hours after the call ends. The conference call will also be available by
webcast on the Company's web site at www.cambridgeheart.com.
About the Cambridge Heart Microvolt T-Wave Alternans Test
The Cambridge Heart Microvolt T-Wave Alternans Test measures extremely subtle
beat-to-beat fluctuations in a person's heartbeat called T-wave alternans. These tiny
heartbeat variations - measured at one millionth of a volt - are detected in any clinical
setting where titration of the heart rate is possible. The preparation for the test
consists of placing proprietary sensors on a patient's chest. Extensive clinical research
has shown that patients with symptoms of or at risk of life threatening arrhythmias who
test positive for T-wave alternans are at significant risk for subsequent sudden cardiac
events including sudden death, while those who test negative are at minimal risk.
About Cambridge Heart, Inc.
Cambridge Heart is engaged in the research, development and commercialization of
products for the non-invasive diagnosis of cardiac disease. Using innovative technologies,
the Company is addressing such key problems in cardiac diagnosis as the identification of
those at risk of sudden cardiac arrest. The Company's products incorporate its proprietary
technology, Microvolt T-Wave Alternans, and is the first diagnostic tool cleared by the
U.S. Food and Drug Administration to non-invasively measure microvolt levels of T-wave
alternans. The Company, founded in 1990, is based in Bedford, Massachusetts and is traded
on the OTCBB under the symbol CAMH. Cambridge Heart can be found on the World Wide Web at
www.cambridgeheart.com
CONTACT: At Cambridge Heart, Inc.
Roderick de Greef, 781-271-1200 ext. 231
roderickd@cambridgeheart.com
or
At Consulting for Strategic Growth
Stanley Wunderlich, 800-625-2236
Info@cfsg1.com
SOURCE: Cambridge Heart, Inc.
